Search Results

RAPT Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma.

The regulator has placed a clinical hold on RAPT Therapeutics’ drug zelnecirnon, which was being investigated in atopic dermatitis and asthma, after a patient experienced liver failure.

RAPT Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2023.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced).

RAPT Therapeutics, Inc. today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.

RAPT Therapeutics, Inc. announced that members of the RAPT management team will participate in the following investor conferences in November.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 a.m. Pacific Time.

RAPT Therapeutics, Inc. today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 2:00 p.m. ET.